As a result, BCR-ABL tyrosine kinase inhibitors have emerged as a proposed strategy for the treatment of chronic myelogenous leukemia [15]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.